



Santalís Pharmaceuticals Signs Exclusive License Agreement with Global Pharmaceutical Company to Commercialize OTC Dermatology Products

February 26, 2014 06:00 AM Eastern Standard Time

SAN ANTONIO--([BUSINESS WIRE](#))--**Santalís Pharmaceuticals Inc.**, a joint venture with TFS Corporation Ltd., of Australia (ASX: TFC) is pleased to report the execution of an exclusive license agreement with a global pharmaceutical company for the marketing of a number of over-the-counter (OTC) dermatology products containing TFS' sustainably cultivated, pharmaceutical-grade East Indian Sandalwood Oil (EISO). The pharmaceutical partner is exclusively dedicated to dermatology and is a world leader in dermatology products with an extensive product portfolio available in 80 countries. The long-term license agreement provides for upfront and milestone payments and royalties based on product sales. The license agreement anticipates worldwide commercialization of the OTC products, with an initial product launch in the U.S. anticipated at the end of 2014.

In addition to its OTC products, Santalis is developing a range of prescription drug candidates. The company's first prescription drug candidate, a topical formulation of EISO to treat pediatric eczema, is expected to enter the clinic in the US in early 2015.

Dr. Paul Castella, Santalis' CEO, stated, "This agreement is an important milestone for our product and clinical development program, and has been achieved just three years into our joint venture with TFS. The quality of our pharmaceutical partner, their longstanding dedication to patient wellbeing, and their ambitions for the products in the marketplace are a testament to the efficacy and clinical benefit of sustainable sandalwood oil-based products in the treatment of important dermatological conditions."

Mr. Frank Wilson, CEO of TFS said "Santalís' agreement with a leading pharmaceutical partner is the first of many such product opportunities, and validates the value of EISO as a natural ingredient in the rapidly expanding global market for dermatology, which is currently estimated to exceed \$20B. Our long term, exclusive supply agreement with Santalis was pivotal to their ability to secure the commitment of a world-class partner."

ABOUT SANTALIS

Santalís Pharmaceuticals, Inc., a 50:50 joint venture with TFS Corporation, Ltd., of Australia, is developing scientifically and clinically validated healthcare products that utilize TFS' cultivated, sustainable, pharmaceutical-grade East Indian Sandalwood Oil (EISO). Santalis' initial product offerings are focused in dermatology, where EISO's well documented anti-microbial, anti-inflammatory and non-irritating properties are expected to be particularly well suited to a number of prevalent and under-served conditions (such as acne, eczema, redness and sensitive skin).

ABOUT TFS

TFS Corporation Ltd (ASX: TFC) is an owner and manager of the world's largest East Indian sandalwood plantations. TFS' first planting in northern Australia was in 1999 and it now manages approximately 7,600 hectares on behalf of both retail and institutional investors. TFS is committed to adopting and maintaining the highest environmental and ethical standards in all aspects of its business and is ranked as an industry leader in ethical and sustainable practices by Oekom Research, a leading international ratings agency. In 2009, TFS entered the prestigious Forbes Asia Pacific's 'Best Under a Billion', which recognizes the Top 200 companies from more than 25,326 publicly-listed firms in the Asia/Pacific region with revenue of less than \$1 billion.

Contacts

Santalís Pharmaceuticals Inc.
Dr. Paul Castella, CEO, 210-399-2316
paul@santalispharma.com